| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,190,000 |
| Market
Cap: |
10.84(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
426,157 |
| 52
Week Range: |
$67.31 - $157.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 16.7 |
| Insider 3/6 Months : 17.3 |
|
| Guru Rank Number : 983 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
75,225 |
143,757 |
247,027 |
| Total Buy Value |
$0 |
$5,942,300 |
$13,295,068 |
$24,257,422 |
| Total People Bought |
0 |
2 |
3 |
3 |
| Total Buy Transactions |
0 |
2 |
5 |
7 |
| Total Shares Sold |
24,096 |
24,096 |
39,096 |
39,954 |
| Total Sell Value |
$2,990,141 |
$2,990,141 |
$4,590,941 |
$4,685,252 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
6 |
7 |
8 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barry Richard |
Director |
– • – |
2019-09-12 |
4 |
B |
$87.49 |
$147,950 |
D/D |
1,691 |
3,183,756 |
2.39 |
- |
|
| Bonney Michael W |
Director |
– • – |
2019-09-09 |
4 |
B |
$86.74 |
$173,480 |
D/D |
2,000 |
7,051 |
2.39 |
- |
|
| Behrens M Kathleen |
Director |
– • – |
2019-09-06 |
4 |
B |
$87.98 |
$219,950 |
D/D |
2,500 |
125,667 |
2.39 |
- |
|
| Behrens M Kathleen |
Director |
– • – |
2019-09-05 |
4 |
OE |
$7.80 |
$39,000 |
D/D |
5,000 |
123,167 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-08-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
42,535 |
30,179 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-08-21 |
4 |
D |
$101.50 |
$5,832,698 |
D/D |
(57,465) |
72,714 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-08-21 |
4 |
OE |
$23.85 |
$2,385,000 |
D/D |
100,000 |
130,179 |
|
- |
|
| Barry Richard |
Director |
– • – |
2019-08-20 |
4 |
B |
$99.32 |
$496,593 |
D/D |
5,000 |
3,182,065 |
2.39 |
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-08-15 |
4 |
OE |
$13.71 |
$241,232 |
D/D |
9,754 |
30,179 |
|
- |
|
| Barry Richard |
Director |
– • – |
2019-08-14 |
4 |
B |
$122.50 |
$453,250 |
D/D |
3,700 |
3,177,065 |
2.39 |
- |
|
| Barry Richard |
Director |
– • – |
2019-08-12 |
4 |
B |
$122.50 |
$159,250 |
D/D |
1,300 |
3,173,365 |
2.39 |
- |
|
| Ingram Douglas S |
President & CEO |
• • – |
2019-08-12 |
4 |
B |
$122.76 |
$2,000,160 |
D/D |
16,252 |
432,197 |
2.81 |
- |
|
| Oneill Gilmore Neil |
EVP, R&D & CMO |
• – – |
2019-05-24 |
4 |
D |
$119.31 |
$552,405 |
D/D |
(4,630) |
7,370 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2019-05-23 |
4 |
S |
$120.00 |
$1,200,000 |
D/D |
(10,000) |
11,717 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2019-05-23 |
4 |
OE |
$7.80 |
$78,000 |
D/D |
10,000 |
21,717 |
|
- |
|
| Oneill Gilmore Neil |
EVP, R&D & CMO |
• – – |
2019-05-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
|
- |
|
| Cumbo Alexander |
EVP, Chief Commercial Officer |
• – – |
2019-03-28 |
4 |
D |
$118.68 |
$256,942 |
D/D |
(2,165) |
11,161 |
|
- |
|
| Cumbo Alexander |
EVP, Chief Commercial Officer |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,876 |
13,326 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-03-28 |
4 |
D |
$118.68 |
$350,462 |
D/D |
(2,953) |
20,425 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,649 |
23,378 |
|
- |
|
| Howton David T |
EVP, General Counsel |
• – – |
2019-03-28 |
4 |
D |
$118.68 |
$280,322 |
D/D |
(2,362) |
18,703 |
|
- |
|
| Howton David T |
EVP, General Counsel |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,319 |
21,065 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-03-19 |
4 |
D |
$126.47 |
$331,984 |
D/D |
(2,625) |
16,729 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2019-03-19 |
4 |
OE |
$13.71 |
$332,308 |
D/D |
15,486 |
19,354 |
|
- |
|
| Barry Richard |
Director |
– • – |
2019-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
1,633 |
3,172,065 |
|
- |
|
360 Records found
|
|
Page 8 of 15 |
|
|
1.38 (1.08%) 
